Vertex Pharmaceuticals Inc (VRTX)
402.43
+9.66
(+2.46%)
USD |
NASDAQ |
May 01, 16:00
402.43
0.00 (0.00%)
After-Hours: 20:00
Vertex Pharmaceuticals Cash from Financing (Quarterly): -119.80M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -119.80M |
| September 30, 2023 | -165.00M |
| June 30, 2023 | 17.30M |
| March 31, 2023 | -294.70M |
| December 31, 2022 | 40.20M |
| September 30, 2022 | -60.20M |
| June 30, 2022 | 47.70M |
| March 31, 2022 | -95.40M |
| December 31, 2021 | -336.20M |
| September 30, 2021 | -656.70M |
| June 30, 2021 | 33.60M |
| March 31, 2021 | -518.70M |
| December 31, 2020 | -125.21M |
| September 30, 2020 | -140.68M |
| June 30, 2020 | 120.02M |
| March 31, 2020 | -359.43M |
| December 31, 2019 | 161.45M |
| September 30, 2019 | 20.36M |
| June 30, 2019 | -13.02M |
| March 31, 2019 | -41.99M |
| December 31, 2018 | -101.05M |
| September 30, 2018 | 2.079M |
| June 30, 2018 | -51.21M |
| March 31, 2018 | 78.96M |
| December 31, 2017 | 73.23M |
| Date | Value |
|---|---|
| September 30, 2017 | 152.70M |
| June 30, 2017 | 132.03M |
| March 31, 2017 | -289.56M |
| December 31, 2016 | 93.76M |
| September 30, 2016 | 13.55M |
| June 30, 2016 | 21.25M |
| March 31, 2016 | 4.702M |
| December 31, 2015 | 52.64M |
| September 30, 2015 | 49.67M |
| June 30, 2015 | 36.20M |
| March 31, 2015 | 50.41M |
| December 31, 2014 | 108.18M |
| September 30, 2014 | 357.23M |
| June 30, 2014 | 33.40M |
| March 31, 2014 | 50.42M |
| December 31, 2013 | 84.05M |
| September 30, 2013 | 13.01M |
| June 30, 2013 | 157.49M |
| March 31, 2013 | -6.135M |
| December 31, 2012 | 4.837M |
| September 30, 2012 | 8.15M |
| June 30, 2012 | 137.69M |
| March 31, 2012 | 21.52M |
| December 31, 2011 | -182.98M |
| September 30, 2011 | 20.07M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-656.70M
Minimum
Sep 2021
161.45M
Maximum
Dec 2019
-128.65M
Average
-95.40M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | 2.754B |
| Eli Lilly and Co | 3.545B |
| Regeneron Pharmaceuticals Inc | -446.10M |
| Alpine Immune Sciences Inc | 156.61M |
| Moderna Inc | -109.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 234.60M |
| Cash from Investing (Quarterly) | -886.50M |
| Free Cash Flow | 3.279B |
| Free Cash Flow Per Share (Quarterly) | 0.4544 |
| Free Cash Flow to Equity (Quarterly) | 118.50M |
| Free Cash Flow to Firm (Quarterly) | 118.50M |
| Free Cash Flow Yield | 3.13% |